| Despite advances in female representation among biopharma’s C-suites—up to 21% this year, according to McKinsey and the nonprofit Lean In—parity is still out of reach, with more than a few broken rungs keeping women from moving up the corporate ladder. Still, hiring and promotion rates are seeing improvements as well, driven in part by women in top-level roles looking to add more diversity to their organizations and encouraging other women in STEM fields. Each year, we spotlight the Fiercest Women in Life Sciences, across every role and sector. Read on below to see our class of 2019. | |
|
Featured Story | | | Monday, November 11, 2019 More women have climbed to the top of the corporate ladder than ever before. This report recognizes 20 of them: women at the top of the life sciences field who lead the change in everything from research to business development and regulatory effort, or have outright built and run their own companies. |
|
|---|
|
Top Stories Of The Week Tuesday, November 12, 2019 Finding the perfect name is no easy task for a new company, particularly in the exotic world of biopharma monikers. Mylan and Pfizer's Upjohn business, working to close their generics megamerger, believe they have one that strikes the right tone—even if that name is very familiar to one of the partners. Tuesday, November 12, 2019 Amgen has given notice of its intent to lay off 149 people at its Cambridge, Massachusetts, operation by the end of the year. The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations in a move that would threaten around 180 jobs. Friday, November 8, 2019 A jury ordered Biogen to pay nearly $6 million to a former sales manager, Danita Erickson, who raised concerns about a colleague's violation of the False Claims Act. Instead of backing her up, her boss focused on her migraines, cut her out of communications and later fired her, the suit alleged. Monday, November 11, 2019 Bolt Biotherapeutics, founded by Stanford immuno-oncology veteran Edgar Engleman, is developing new class of cancer drugs called immune stimulating antibody conjugates. Backed by fresh data from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator, the company is preparing a phase 1 trial. Monday, November 11, 2019 AbbVie could issue $28 billion in bonds as soon as Tuesday to help fund its massive Allergan buyout, Bloomberg reports—the fourth largest in history. But CEO Richard Gonzalez says he's not worried about handling the load. Combined, the two companies churned out $19 billion in cash last year. Wednesday, November 13, 2019 Merck has struck a deal to buy Calporta Therapeutics for up to $576 million. The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain. Friday, November 8, 2019 Bristol-Myers Squibb's $74 billion pending pickup of Celgene has notched a win already with an FDA approval for JAK med Inrebic. Now, the consummation has grabbed another victory with an approval for a Celgene blood disease candidate—and it could spell blockbuster sales ahead. Tuesday, November 12, 2019 AstraZeneca is planning to file for approval of anifrolumab in systemic lupus erythematosus in the second half of next year. The Big Pharma is confident data generated across mid- and late-phase trials show the anti-IFNAR1 antibody works despite a pivotal study missing its primary goal. Wednesday, November 13, 2019 After the FDA issued a global recall last year of "sartan"-based drugs contaminated with a possible carcinogen, there's been plenty of blame to pass around. The most recent recipient of regulators' ire is Mylan, which was knocked with a warning letter criticizing procedures at an Indian plant. Friday, November 8, 2019 Corindus Vascular Robotics reported that it has completed its first machine-assisted brain surgery procedure in humans. Enrollment Showcase Resources Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 
